Search research articles
Contact Us
Filters
Showing results (1-10 of 17) with videos related to
Page
of 2
Sort By:
Methods (San Diego, Calif.)
|
August 25, 2004
Automated systems for protein crystallization
Joel Bard, Kimberly Ercolani, Kristine Svenson, et al.
The Journal of Biological Chemistry
|
April 21, 2004
Crystal structure of the toluene/o-xylene monooxygenase hydroxylase from Pseudomonas stutzeri OX1. Insight into the substrate specificity, substrate channeling, and active site tuning of multicomponent monooxygenases
Matthew H Sazinsky, Joel Bard, Alberto Di Donato, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 2, 2012
Identification of pyrimidine derivatives as hSMG-1 inhibitors
Ariamala Gopalsamy, Eric M Bennett, Mengxiao Shi, et al.
Nature
|
January 25, 2002
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin
Chester L Drum, Shui-Zhong Yan, Joel Bard, et al.
Antimicrobial Agents and Chemotherapy
|
June 19, 2008
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796
Anita Y M Howe, Huiming Cheng, Stephen Johann, et al.
The Journal of Biological Chemistry
|
November 13, 2001
Identification, characterization, and crystal structure of Bacillus subtilis nicotinic acid mononucleotide adenylyltransferase
Andrea M Olland, Kathryn W Underwood, Robert M Czerwinski, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 2, 2010
Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
Hwei-Ru Tsou, Gloria MacEwan, Gary Birnberg, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 23, 2020
A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics
Hannah M Jones, John Tolsma, Zhiwei Zhang, et al.
The Journal of Biological Chemistry
|
October 31, 2015
A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv)
Chao Tu, Virginie Terraube, Amy Sze Pui Tam, et al.
Journal of Medicinal Chemistry
|
March 13, 2009
A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)
Wei Li, Jianchang Li, Yuchuan Wu, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 17) with videos related to
Sort By:
Page
of 2
Methods (San Diego, Calif.)
|
August 25, 2004
Automated systems for protein crystallization
Joel Bard, Kimberly Ercolani, Kristine Svenson, et al.
The Journal of Biological Chemistry
|
April 21, 2004
Crystal structure of the toluene/o-xylene monooxygenase hydroxylase from Pseudomonas stutzeri OX1. Insight into the substrate specificity, substrate channeling, and active site tuning of multicomponent monooxygenases
Matthew H Sazinsky, Joel Bard, Alberto Di Donato, et al.
Bioorganic & Medicinal Chemistry Letters
|
October 2, 2012
Identification of pyrimidine derivatives as hSMG-1 inhibitors
Ariamala Gopalsamy, Eric M Bennett, Mengxiao Shi, et al.
Nature
|
January 25, 2002
Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin
Chester L Drum, Shui-Zhong Yan, Joel Bard, et al.
Antimicrobial Agents and Chemotherapy
|
June 19, 2008
Molecular mechanism of hepatitis C virus replicon variants with reduced susceptibility to a benzofuran inhibitor, HCV-796
Anita Y M Howe, Huiming Cheng, Stephen Johann, et al.
The Journal of Biological Chemistry
|
November 13, 2001
Identification, characterization, and crystal structure of Bacillus subtilis nicotinic acid mononucleotide adenylyltransferase
Andrea M Olland, Kathryn W Underwood, Robert M Czerwinski, et al.
Bioorganic & Medicinal Chemistry Letters
|
March 2, 2010
Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
Hwei-Ru Tsou, Gloria MacEwan, Gary Birnberg, et al.
CPT: Pharmacometrics & Systems Pharmacology
|
July 23, 2020
A Physiologically-Based Pharmacokinetic Model for the Prediction of "Half-Life Extension" and "Catch and Release" Monoclonal Antibody Pharmacokinetics
Hannah M Jones, John Tolsma, Zhiwei Zhang, et al.
The Journal of Biological Chemistry
|
October 31, 2015
A Combination of Structural and Empirical Analyses Delineates the Key Contacts Mediating Stability and Affinity Increases in an Optimized Biotherapeutic Single-chain Fv (scFv)
Chao Tu, Virginie Terraube, Amy Sze Pui Tam, et al.
Journal of Medicinal Chemistry
|
March 13, 2009
A selective matrix metalloprotease 12 inhibitor for potential treatment of chronic obstructive pulmonary disease (COPD): discovery of (S)-2-(8-(methoxycarbonylamino)dibenzo[b,d]furan-3-sulfonamido)-3-methylbutanoic acid (MMP408)
Wei Li, Jianchang Li, Yuchuan Wu, et al.
Page
of 2